Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment.

Launched by ·

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called Tetuzumab (IBI311) for people with moderate to severe thyroid-associated ophthalmopathy (TAO), an eye condition related to thyroid disease. TAO can cause symptoms like eye swelling, discomfort, and in serious cases, vision problems or even blindness. This study focuses on patients who still have active symptoms after receiving standard steroid treatment (glucocorticoids). The goal is to see if Tetuzumab can safely improve eye symptoms by targeting specific cells that contribute to the disease, and to better understand how well this treatment works in this group of patients.

People eligible for this trial are adults with moderate to severe active TAO who have already undergone steroid treatment but still have symptoms. Participants will receive Tetuzumab and be closely monitored to check for improvements and any side effects. This study is currently recruiting adults of all genders who meet the criteria. If you or a loved one has ongoing eye problems linked to thyroid disease despite steroid treatment, this trial may offer a new option to explore with your doctor.

Gender

ALL

Eligibility criteria